{
    "balance": {
        "data": [
            "CONSOLIDATED BALANCE SHEETS\t(Unaudited)\tApril 1,\tDecember 31,\t(In millions except share and per share amounts)\t2023\t2022\tAssets\tCurrent assets:\tCash and cash equivalents\t$\t3,482\t$\t8,524\tAccounts receivable, less allowances of $\t190\tand $\t189\t7,922\t8,115\tInventories\t5,664\t5,634\tContract assets, net\t1,375\t1,312\tOther current assets\t1,766\t1,644\tTotal current assets\t20,209\t25,229\tProperty, plant and equipment, net\t9,354\t9,280\tAcquisition-related intangible assets, net\t17,972\t17,442\tOther assets\t3,983\t4,007\tGoodwill\t43,140\t41,196\tTotal assets\t$\t94,658\t$\t97,154\tLiabilities, redeemable noncontrolling interest and equity\tCurrent liabilities:\tShort-term obligations and current maturities of long-term obligations\t$\t6,122\t$\t5,579\tAccounts payable\t2,798\t3,381\tAccrued payroll and employee benefits\t1,307\t2,095\tContract liabilities\t2,662\t2,601\tOther accrued expenses\t2,995\t3,354\tTotal current liabilities\t15,884\t17,010\tDeferred income taxes\t2,976\t2,849\tOther long-term liabilities\t4,230\t4,238\tLong-term obligations\t29,135\t28,909\tRedeemable noncontrolling interest\t123\t116\tEquity:\tThermo Fisher Scientific Inc. shareholders  equity:\tPreferred stock, $\t100\tpar value,\t50,000\tshares authorized;\tnone\tissued\t \t \tCommon stock, $\t1\tpar value,\t1,200,000,000\tshares authorized;\t441,166,292\tand\t440,668,112\tshares issued\t441\t441\tCapital in excess of par value\t16,889\t16,743\tRetained earnings\t43,064\t41,910\tTreasury stock at cost,\t55,445,006\tand\t50,157,275\tshares\t(\t15,083\t)\t(\t12,017\t)\tAccumulated other comprehensive income/(loss)\t(\t3,054\t)\t(\t3,099\t)\tTotal Thermo Fisher Scientific Inc. shareholders  equity\t42,257\t43,978\tNoncontrolling interests\t53\t54\tTotal equity\t42,310\t44,032\tTotal liabilities, redeemable noncontrolling interest and equity\t$\t94,658\t$\t97,154\tThe accompanying notes are an integral part of these condensed consolidated financial statements.\t3\tTHERMO FISHER SCIENTIFIC INC.\tCONDENSED CONSOLIDATED STATEMENTS OF INCOME\t(Unaudited)\tThree months ended\tApril 1,\tApril 2,\t(In millions except per share amounts)\t2023\t2022\tRevenues\tProduct revenues\t$\t6,404\t$\t8,017\tService revenues\t4,306\t3,801\tTotal revenues\t10,710\t11,818\tCosts and operating expenses:\tCost of product revenues\t3,337\t3,555\tCost of service revenues\t3,233\t2,799\tSelling, general and administrative expenses\t2,119\t2,277\tResearch and development expenses\t346\t364\tRestructuring and other costs\t112\t2\tTotal costs and operating expenses\t9,147\t8,997\tOperating income\t1,563\t2,821\tInterest income\t146\t18\tInterest expense\t(\t300\t)\t(\t136\t)\tOther income/(expense)\t(\t46\t)\t(\t163\t)\tIncome before income taxes\t1,363\t2,540\tProvision for income taxes\t(\t46\t)\t(\t301\t)\tEquity in earnings/(losses) of unconsolidated entities\t(\t25\t)\t(\t19\t)\tNet income\t1,292\t2,220\tLess: net income/(losses) attributable to noncontrolling interests and redeemable noncontrolling interest\t3\t5\tNet income attributable to Thermo Fisher Scientific Inc.\t$\t1,289\t$\t2,215\tEarnings per share attributable to Thermo Fisher Scientific Inc.\tBasic\t$\t3.34\t$\t5.66\tDiluted\t$\t3.32\t$\t5.61\tWeigh"
        ],
        "timestamp": "2025-01-21_09-41-28"
    }
}